ArticleFrontiers in medicine2026
Propensity-matched study of liposomal doxorubicin vs. doxorubicin in first-line DLBCL treatment: efficacy and safety.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Given the increasing use of pegylated liposomal doxorubicin (PLD) in diffuse large B-cell lymphoma (DLBCL) treatment due to its advantages in reducing adverse reactions, and the uncertainty surrounding its effective dose and corresponding efficacy in DLBCL, this study aims to compare it with the standard dose of conventional doxorubicin (DOX) in first-line DLBCL treatment. Methods: A retrospective propensity score-matched analysis of 512 DLBCL patients (2018-2023) compared PLD {stratified: low-dose [21.5 (5-25.5) mg/m Results: Overall PLD and DOX showed comparable 2-year PFS (74.3% vs. 69.6%, Conclusion: High-dose PLD [29.5 (25.5-40) mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.